Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of oral aprepitant + ondansetron in breast cancer ADC therapy
ChiCTR2500109080Phase 4Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aprepitant and ondansetron in breast cancer, Non-hematologic malignancy and hematopoietic malignancies, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Complete response rate during overall treatment period (0–120 hours). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
aprepitantondansetron
03
Conditions
breast cancerNon-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2500109080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109080.